# Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

> **NCT03140176** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03140176
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-15
- **Primary completion:** 2022-01-22
- **Final completion:** 2022-01-22
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** The study was terminated early due to the inability to recruit the planned number of patients
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03140176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03140176, "Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03140176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*